Bank of New York Mellon Corp Decreases Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Bank of New York Mellon Corp decreased its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 8.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,673,994 shares of the company's stock after selling 156,527 shares during the period. Bank of New York Mellon Corp owned about 0.63% of Autolus Therapeutics worth $3,934,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bellevue Group AG raised its stake in Autolus Therapeutics by 27.7% in the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company's stock valued at $151,000 after purchasing an additional 9,000 shares during the last quarter. State Street Corp raised its stake in Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company's stock valued at $2,202,000 after purchasing an additional 10,401 shares during the last quarter. Capstone Investment Advisors LLC acquired a new position in Autolus Therapeutics in the 3rd quarter valued at $51,000. HighVista Strategies LLC raised its stake in Autolus Therapeutics by 2.7% in the 3rd quarter. HighVista Strategies LLC now owns 533,024 shares of the company's stock valued at $1,935,000 after purchasing an additional 14,204 shares during the last quarter. Finally, Dumont & Blake Investment Advisors LLC acquired a new position in Autolus Therapeutics in the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

Remove Ads

Autolus Therapeutics Stock Up 1.5 %

Shares of AUTL traded up $0.03 during midday trading on Friday, reaching $1.70. The company had a trading volume of 1,642,335 shares, compared to its average volume of 1,377,938. The firm has a 50 day simple moving average of $2.02 and a 200-day simple moving average of $2.92. The stock has a market cap of $452.36 million, a PE ratio of -1.40 and a beta of 2.07. Autolus Therapeutics plc has a 1-year low of $1.56 and a 1-year high of $6.60.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million. As a group, sell-side analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on AUTL shares. Wells Fargo & Company reduced their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $9.52.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.